Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
Transgene’s Phase I trial will take place in six centres in France and should enrol 20 patients. The primary endpoints are to assess the safety and maximum tolerated dose of TG4023. Eligible patients will have at least one unresectable tumour in the liver and no other option for treatment or care. Each patient will receive one percutaneous injection into the hepatic tumour followed by the administration of 5-FC. Several dose levels of TG4023 will be administered in successive cohorts in order to define the maximum tolerated dose. Transgene expects to report preliminary safety data in the third quarter of 2010, with complete data planned by the first quarter of 2011.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.